The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
May 6th 2024
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
Dr. Figlin Describes the Efficacy of AGS-003 in mRCC
February 1st 2014Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)
Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD
November 19th 2013Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.
Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer
August 28th 2013Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.
Early Results Robust for New PD-L1 Immunotherapy Agent
May 15th 2013An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.
AGS-003 Vaccine Achieves Survival Benefits in mRCC
March 26th 2013AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.